{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:27Z","timestamp":1740107427956,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Unter der Federf\u00fchrung der Deutschen Gesellschaft f\u00fcr Neurologie und Beteiligung vieler weiterer Fachgesellschaften wurde die S2k-Leitlinie zu Myositissyndromen vollst\u00e4ndig aktualisiert und \u00fcberarbeitet. Bei der Klassifikation der Myositiden werden nun die immunmediierte nekrotisierende Myopathie und das Antisynthetasesyndrom als eigenst\u00e4ndige Entit\u00e4ten aufgefasst. Bez\u00fcglich der Diagnostik gibt die Leitlinie konkrete Empfehlungen zum Dysphagiescreening, insbesondere bei der Einschlussk\u00f6rperchenmyositis, und zur Tumordiagnostik bei bestimmten Myositisformen. In der Therapie steht nach der positiven ProDERM-Studie mit intraven\u00f6sen Immunglobulinen (Octagam\u00ae) ein zugelassenes Pr\u00e4parat zur Verf\u00fcgung. Auf Basis der INBUILD-Studie ist Nintedanib als antifibrotische Therapie bei progressiv fibrosierender Lungenbeteiligung verf\u00fcgbar. Die aktualisierte Leitlinie stellt ein f\u00fcr Rheumatolog*innen praxistaugliches Dokument mit zahlreichen Empfehlungen zur Versorgung von Myositispatient*innen dar.<\/jats:p>","DOI":"10.1007\/s00393-022-01278-2","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:02:30Z","timestamp":1665676950000},"page":"868-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myositis"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-5680","authenticated-orcid":false,"given":"Peter","family":"Korsten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"1278_CR1","doi-asserted-by":"publisher","first-page":"e23677","DOI":"10.1097\/MD.0000000000023677","volume":"100","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal\u00a0R, Charles-Schoeman\u00a0C, Schessl\u00a0J et al (2021) Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10\u202f% in patients with dermatomyositis (\u201cProDERM Study\u201d). Medicine 100:e23677. https:\/\/doi.org\/10.1097\/MD.0000000000023677","journal-title":"Medicine"},{"key":"1278_CR2","unstructured":"AWMF: Detail. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/030-054.html. Zugegriffen: 27. Juli 2022"},{"key":"1278_CR3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V et\u00a0al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 381:1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"1278_CR4","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.semarthrit.2022.151959","volume":"53","author":"M McPherson","year":"2022","unstructured":"McPherson\u00a0M, Economidou\u00a0S, Liampas\u00a0A et al (2022) Management of MDA\u20115 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum 53:151959. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151959","journal-title":"Semin Arthritis Rheum"},{"key":"1278_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","volume":"22","author":"R Zeng","year":"2020","unstructured":"Zeng\u00a0R, Schmidt\u00a0J (2020) Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep 22:74. https:\/\/doi.org\/10.1007\/s11926-020-00950-3","journal-title":"Curr Rheumatol Rep"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01278-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T12:05:37Z","timestamp":1670501137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01278-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01278-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"15 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Korsten gibt unabh\u00e4ngig von diesem Artikel Reisekostenunterst\u00fctzung von AbbVie und Chugai an und erhielt Vortrags- und Beratungshonorare von AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, Galapagos, GlaxoSmithKline, Janssen-Cilag, Lilly, Pfizer und Sanofi-Aventis. Zudem erhielt seine Institution Studiendrittmittel von AstraZeneca, Boehringer-Ingelheim, Diamed Medizintechnik GmbH, Galapagos, GlaxoSmithKline und Novartis, ebenfalls nicht in Verbindung mit diesem Artikel. P.\u00a0Korsten ist aktuell zweiter Vorsitzender der <i>International Myositis Society<\/i>. E.\u00a0Feist gibt unabh\u00e4ngig von diesem Artikel Berater- und Gutachtert\u00e4tigkeiten f\u00fcr AbbVie, BMS, Lilly, MSD, Roche, Novartis, Pfizer und Sanofi-Aventis, Mitarbeit in \u201eadvisory boards\u201c von BMS, Lilly, MSD, Novartis und Sanofi-Aventis sowie Vortragshonorare von Lilly und Novartis an. Zudem erhielt er Studiendrittmittel von Novartis, ebenfalls unabh\u00e4ngig von diesem Artikel. Beide Autoren haben als Vertreter der Deutschen Gesellschaft f\u00fcr Rheumatologie bei der Erstellung der Leitlinie mitgewirkt.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}